TY  - JOUR
AU  - Peters, Solange
AU  - Danson, Sarah
AU  - Ejedepang, Dunson
AU  - Dafni, Urania
AU  - Hasan, Baktiar
AU  - Radcliffe, Hoi-Shen
AU  - Bustin, Frederique
AU  - Crequit, Jacky
AU  - Coate, Linda
AU  - Guillot, Monica
AU  - Surmont, Veerle
AU  - Rauch, Daniel
AU  - Rudzki, Jakob
AU  - O'Mahony, Deirdre
AU  - Barneto Aranda, Isidoro
AU  - Scherz, Amina
AU  - Tsourti, Zoi
AU  - Roschitzki-Voser, Heidi
AU  - Pochesci, Alessia
AU  - Demonty, Gaston
AU  - Stahel, Rolf A
AU  - O'Brien, Mary
PY  - 2021
DO  - 10.1016/j.lungcan.2021.09.002
UR  - https://hdl.handle.net/10668/24894
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - The efficacy of adding denosumab to standard first-line chemotherapy for advanced NSCLC patients has been evaluated in two separate randomised trials (SPLENDOUR and AMGEN-249). In this pooled analysis, we will assess the combination-treatment effect...
LA  - en
KW  - BONE METASTASES
KW  - DENOSUMAB
KW  - NSCLC
KW  - RANKL
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Denosumab
KW  - Humans
KW  - Lung Neoplasms
KW  - Progression-Free Survival
TI  - Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
TY  - research article
VL  - 161
ER  -